Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in β-phenylethylamine

Kitaichi, Yuji; Inoue, Takeshi; Nakagawa, Shin; Boku, Shuken; Izumi, Takeshi; Koyama, Tsukasa

Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in β-phenylethylamine

Kitaichi, Yuji; Inoue, Takeshi; Nakagawa, Shin et al.

European Journal of Pharmacology, 2010, 637(1-3), 77-82

Permalink : https://hdl.handle.net/2115/43296

このアイテムのアクセス数:1,469件（2026-05-11 08:34 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
EJP637-1-3_77-82	pdf	564 KB	1,544

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/43296
タイトル	Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in β-phenylethylamine
著者	Kitaichi, Yuji ; Inoue, Takeshi ; Nakagawa, Shin ; Boku, Shuken ; Izumi, Takeshi ; Koyama, Tsukasa
e-Rad_Researcher 80374445 著者名 Kitaichi, Yuji
e-Rad_Researcher 70250438 著者名 Inoue, Takeshi
e-Rad_Researcher 60360905 著者名 Nakagawa, Shin
e-Rad_Researcher 60455665 著者名 Boku, Shuken
e-Rad_Researcher 60312360 著者名 Izumi, Takeshi
e-Rad_Researcher 10113557 著者名 Koyama, Tsukasa
言語	英語
キーワード	MAO-A (monoamine oxidase A) inhibitor
	MAO-B (monoamine oxidase B) inhibitor
	β-Phenylethylamine
	Noradrenaline
	Serotonin
	In vivo microdialysis
発行日	2010-07-10
出版者	Elsevier B.V.
収録物名	European Journal of Pharmacology
巻(号)	637(1-3)
ページ	77-82
抄録	Monoamine oxidase inhibitors (MAO inhibitors) have been widely used as antidepressants. However, it remains unclear whether a difference exists between non-selective MAO inhibitors and selective MAO-A inhibitors in terms of their antidepressant effects. Using in vivo microdialysis methods, we measured extracellular noradrenaline and serotonin levels following administration of Ro 41-1049, a reversible MAO-A inhibitor and/or lazabemide, a reversible MAO-B inhibitor in the medial prefrontal cortex (mPFC) of rats. We examined the effect of local infusion of β-phenylethylamine to the mPFC of rats on extracellular noradrenaline and serotonin levels. Furthermore, the concentrations of β-phenylethylamine in the tissue of the mPFC after combined treatment with Ro 41-1049 and lazabemide were measured. The Ro 41-1049 alone and the combined treatment significantly increased extracellular noradrenaline levels compared with vehicle and lazabemide alone. Furthermore, the combined treatment increased noradrenaline levels significantly more than Ro 41-1049 alone did. The Ro 41-1049 alone and the combined treatment significantly increased extracellular serotonin levels compared with vehicle and lazabemide alone, but no difference in serotonin levels was found between the combined treatment group and the Ro 41-1049 group. Local infusion of low-dose β-phenylethylamine increased extracellular noradrenaline levels, but not that of serotonin. Only the combined treatment significantly increased β-phenylethylamine levels in tissues of the mPFC. Our results suggest that the combined treatment with a MAO-A inhibitor and a MAO-B inhibitor strengthens antidepressant effects because the combined treatment increases extracellular noradrenaline levels more than a MAO-A inhibitor alone through increases in β-phenylethylamine.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
PISSN	0014-2999
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1016/j.ejphar.2010.04.014